Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT03009461 Not yet recruiting - Clinical trials for HepatoCellular Carcinoma

Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis

Start date: January 2017
Phase: Phase 2
Study type: Interventional

According to the Barcelona clinic liver cancer (BCLC) staging treatment guideline, sorafenib is recommended for Hepatocellular Carcinoma (HCC) with Portal Vein Tumor Thrombosis (PVTT), but HCC with major PVTT (in the main trunk or 1st-order branches of the portal vein) did not benefit much from sorafenib in previous studies. There is no established standard treatment for HCC patients with major PVTT, the investigators conducted a randomized, phase 2 study to investigate the survival benefit of sorafenib plus Hepatic arterial infusion chemotherapy (HAIC) with Oxaliplatin and Fluorouracil versus sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.

NCT ID: NCT03007225 Completed - Clinical trials for HepatoCellular Carcinoma

Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients

Start date: July 2015
Phase: Phase 4
Study type: Interventional

This study aimed to to compare the conventional transarterial chemoembolization (cTACE) with chemoembolization using doxorubicin drug eluting beads (DEB-TACE) for the treatment of hepatocellular carcinoma regarding short term efficacy and safety in first 3 months after embolization

NCT ID: NCT03006926 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma

Start date: January 2017
Phase: Phase 1
Study type: Interventional

This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC).

NCT ID: NCT02997956 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)

Start date: July 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase IB study design planned to identify the MTD (Maximum Tolerated Dose) of Tocilizumab in HCC (Hepatocellular Carcinoma) patients followed by a phase II design whereupon the primary objective will be median progression free survival (PFS).

NCT ID: NCT02989870 Not yet recruiting - Clinical trials for HepatoCellular Carcinoma

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

Start date: February 2017
Phase: Phase 1
Study type: Interventional

This study involves a course of radiation to up to 5 tumors in the participant's liver followed by systemic therapy. (Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.) The type of radiation is called stereotactic body radiation therapy (SBRT). The purpose of this study is to compare the effects, good and/or bad, of different doses of SBRT given along with the systemic therapies, sorafenib and bavituximab. The researchers want to see which dose of radiation will work best in stimulating the immune response and provide local control to the participant's liver. The usual treatment for hepatocellular carcinoma that is unresectable can be transarterial therapy, sorafenib alone and/or clinical trial.

NCT ID: NCT02988440 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

Start date: May 2017
Phase: Phase 1
Study type: Interventional

A two part study to determine the maximum tolerated dose and/or recommended phase 2 dose of PDR001 in combination with sorafenib in patients with advanced hepatocellular carcinoma in first line. There will be a dose escalation part and a dose expansion part.

NCT ID: NCT02987907 Recruiting - Clinical trials for HepatoCellular Carcinoma

The Impact on Therapeutic Effect and Tolerance of Treatment for Patients With Hepatocellular Carcinoma in Transcatheter Arterial Chemoembolization (TACE) of Dexamethasone Application: A Random, Double-blind, Controlled, Clinical Trial.

Start date: August 2016
Phase: Phase 3
Study type: Interventional

The current random, double-blind, controlled, clinical trial was designed to evaluate the impact on therapeutic effect and tolerance of treatment for patients with hepatocelluclar carcinoma in transcatheter arterial chemoembolization (TACE) of dexamethasone application.

NCT ID: NCT02987699 Recruiting - Clinical trials for HepatoCellular Carcinoma

Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil

Start date: November 2016
Phase: Phase 2
Study type: Interventional

The purpose of this phase II study is to determine the recommended dose, as well as the safety and efficacy of the combination of oxaliplatin, leucovorin and 5-Fu introduced by hepatic arterial infusion chemotherapy (HAIC) in patients with advanced hepatocellular carcinoma (HCC).

NCT ID: NCT02981498 Recruiting - Clinical trials for Hepatocellular Carcinoma

Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma

Start date: June 2015
Phase: Phase 2
Study type: Interventional

To evaluate safety and efficacy of combined hepatic arterial infusion (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin and sorafenib in patients with advanced hepatocellular carcinoma (HCC).

NCT ID: NCT02973685 Recruiting - Clinical trials for HepatoCellular Carcinoma

HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.

Start date: October 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with large hepatocellular carcinoma staged BCLC A/B.